Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 187-190

  Hilkens, P H E ^a   Verweij, J ^a   Vecht, Ch J ^a   Stoter, G ^a   Van Den Bent, M J ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

docetaxel; Lhermitte's sign; neuropathy; taxotere

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; TAXOIDS;

EID: 0031058721     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008245400251     Document Type: Article

References (16)

1. Pronk LC, Stoter G, Verweij J. Docetaxel (taxolere): Single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 1995; 21: 463-78.
2. Hilkens PHE, Verweij J. Stoter G et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-8.
3. Fossella F, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
4. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
5. Aamdal S. Wolff I, Kaplan S et al. Docetaxel (taxotere) in advanced malignant melanoma: A phase II study of the EORTC early clinical trials group. Eur J Cancer 1994; 30A: 1061-4.
6. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a pre-dominantly sensory neuropathy. Neurology 1989; 39: 368-73.
7. van Gerven JMA, Moll JWB, van den Bent MJ et al. Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30A: 1074-7.
8. New PZ, Jackson CE, Rinaldi D et al. Neurotoxicity of docetaxel (taxotere). Neurology 1996; 46: 108-11.
9. Freilich RJ, Balmaceda C, Seidman AD et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115-8.
10. PostmaTJ, Vermorken JB, Liefting AJM et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
11. Hovestadt A, Van der Burg MEL, Verbiest HBC et al. The course of neuropathy after cessation of cisplatin treatment, combined with org 2766 or placebo. J Neurol 1992; 239: 143-146.
12. Hilkens PHE, Planting AST, Van der Burg MEL et al. Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1994; 1: 45-50.
13. van den Bent MJ, van Raaij-van der Aarsen VJM, Verweij J et al. Progression of paclitaxel induced neuropathy following discontinuation of treatment. Muscle Nerve 1996 (in press)
14. Schaumburg HH, Spencer PS. Toxic neuropathies. Neurology 1979; 29: 429-31.
15. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66: 1117-23.
16. van den Bent MJ. Hilkens PHE, van Raaij-van der Aarsen VJM et al. Lhermitte's sign following chemotherapy with docetaxel (submitted).